HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Listerine actives need more plaque, gingivitis data to prove efficacy, FDA plaque subcmte.

This article was originally published in The Rose Sheet

Executive Summary

LISTERINE ACTIVES NEED ADDITIONAL GINGIVITIS, PLAQUE DATA TO PROVE EFFICACY, FDA's Dental Products Panel Plaque Subcommittee Chair Robert Genco, DDS/PhD, State University of New York-Buffalo, said at a May 8-9 meeting in Bethesda, Md. After hearing data from Warner-Lambert on the efficacy of the four active ingredients in 100-year old Listerine -- thymol (.064%), menthol (.042%), eucalyptol (.092%) and methyl salicylate, also known as wintergreen oil (.06%) -- Genco said the subcommittee needs additional data on the antiplaque and antigingivitis effect of the four actives.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel